| pubmed-article:3922631 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0026339 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C1155003 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0596988 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0036576 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:3922631 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:3922631 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3922631 | pubmed:dateCreated | 1985-7-11 | lld:pubmed |
| pubmed-article:3922631 | pubmed:abstractText | Regulation of the growth of murine B-cell lymphomas has been used as a model for tolerance induction. The inhibition by anti-immunoglobulin reagents of the growth of WEHI-231 and several variant clones has now been studied. The parental line is exquisitely sensitive to growth inhibition by heterologous or monoclonal anti-mu or anti-k reagents and ceases to incorporate thymidine within 24-48 hr of exposure to anti-immunoglobulin reagents. Growth inhibition is initially reversible, but prolonged exposure to anti-mu results in cell death. This inhibition is specific for immunoglobulin light and heavy chains since growth is not inhibited by antibodies directed at either class I or class II histocompatibility antigens. In order to study the mechanism of growth inhibition, we have mutagenized WEHI-231 with ethylmethane sulfonate and cloned the surviving colonies in the presence of anti-mu. Such variants, which have been repeatedly recloned, are able to grow normally in the presence of anti-mu up to 100 micrograms/ml. These "resistant" clones, while expressing amounts of surface IgM similar to that observed on WEHI-231, do not differ markedly in their ability to cap their immunoglobulin receptors compared to the parental line but appear to have lost class II antigens. Cell cycle analysis revealed that anti-mu causes a block in the transition of WEHI-231 from G1 to S phase. The relevance of these processes to models of B-cell tolerance induction are discussed. | lld:pubmed |
| pubmed-article:3922631 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3922631 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3922631 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3922631 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3922631 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3922631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3922631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3922631 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3922631 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3922631 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:ScottD WDW | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:TuttleJJ | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:KengPP | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:CogswellJ PJP | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:LivnatDD | lld:pubmed |
| pubmed-article:3922631 | pubmed:author | pubmed-author:HaynesWW | lld:pubmed |
| pubmed-article:3922631 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3922631 | pubmed:volume | 93 | lld:pubmed |
| pubmed-article:3922631 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3922631 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3922631 | pubmed:pagination | 124-31 | lld:pubmed |
| pubmed-article:3922631 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:meshHeading | pubmed-meshheading:3922631-... | lld:pubmed |
| pubmed-article:3922631 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3922631 | pubmed:articleTitle | Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants. | lld:pubmed |
| pubmed-article:3922631 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3922631 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3922631 | lld:pubmed |
